Physiogenex works closely with several scientific partners to provide our clients with innovative solutions, high quality services and scientific excellence.


As a subsidiary of Physiogenex, Cardiomedex shares the same management and facilities, and co-develops innovative in vivo models of cardiometabolism and preclinical services.

Cardiomedex provides expertise in cardiovascular diseases, oncocardiology and neurocardiology to evaluate the cardiovascular effects of drug candidates: myocardial infarction, cardiac arrhythmia, cardiac hypertrophy, heart failure, hypertension, and cardiotoxicity. Cardiomedex services can be applied to Physiogenex’s models providing a complete evaluation of customers’ drugs on cardiometabolic disorders.

Visit the Cardiomedex website for more information.


Based on its pioneering research on the role of tissue microbiota in the initiation of the inflammatory cascade leading to metabolic disorders, Vaiomer’s vocation is to contribute to the discovery of innovative biomarkers, therapeutic targets and products for the early prognosis, prevention and treatment of cardiometabolic diseases.

Vaiomer has developed a unique platform to sequence, analyse and quantify gut, oral, blood and tissue microbiota to further validate nutritional and therapeutic strategies on microbiota dysbiosis-related diseases.

Vaiomer proceeds with the microbiome analysis from samples collected during in vivo animal studies run at Physiogenex. This provides a complete profiling of our client’s drugs benefits from the microbiome to the cardiometabolism. Physiogenex and Vaiomer also share the same advisory board chairman, namely Pr. Rémy Burcelin, an expert in type 2 diabetes, incretins and microbiome.

Visit the Vaiomer website for more information.


CLEA Japan, Inc

Since 1965, CLEA Japan, Inc. is an independent company producing SPF animals with its comprehensive experience and technologies in the spirit of animal welfare. Based on its experience acknowledged by pharmaceutical companies, CLEA Japan, Inc. efficiently provides CRO services to Physiogenex.

Since 2016, CLEA Japan Inc. has worked closely with Physiogenex in the development of the SDT fatty rat as a model of Type 2 diabetic nephropathy, retinopathy and cardiometabolic complications. This collaborative work has been presented in several international meetings such as the ASN Kidney Week, the Internal Society of Nephrology and the Association for Research in Vision and Ophthalmology (ARVO).

Visit the CLEA website for more information.

Central Lab. Animal Inc.

Central Lab. Animal Inc. is an expert supplier of experimental rodents, constantly providing best quality bioservices to researchers. Based on its experience acknowledged by pharmaceutical companies, Central Lab. Animal Inc. efficiently provides CRO services to Physiogenex.

Visit the Central Lab. Animal Inc. website for more information.



CRS Clinical Research Services

CRS Clinical Research Services

CRS Clinical Research Services is your Trusted Partner in Clinical Research. As a healthcare partner, we are highly committed to make our contribution in the development of new drugs that improve patient’s life. Early-phase clinical development is the DNA of our company. Every year, we contribute to helping millions of people and bringing new medicines to market.

We provide you with extensive expertise and outstanding early phase clinical services that deliver premium value to our customers, guaranteeing highest safety to our volunteers and patients.

Utilizing state-of-the-art technology and proven methodologies, we generate high-quality data and provide valuable insights. With our years of experience, specialized knowledge, and dedicated team, we are ideal partner for your clinical study projects.

 Visit the CRS website for more information.

Aiosyn Logo


Aiosyn is a pioneering medical software company that develops precision pathology software for cancer and kidney disease.

Aiosyn’s solutions are integrated into standard pathology workflows, improving clinical decision-making and accelerating drug development. The Aiosyn team has been built upon over 20 years of research experience in the field of pathology and is rooted in the pathology practice.

Visit Aiosyn for more information.